Non-alcoholic steatohepatitis (NASH) is a disease whose incidence is rising and is related to an accumulation of fat in the liver that can lead to its disfunction due to excessive inflammation and fibrosis. No medical treatments yet exist for NASH but
it’s a hopeful time for the field because several drug candidates are in Phase II and III clinical trials. New NASH drug targets are also being revealed due to progress in the fields of NASH contributors: metabolic disfunction, inflammation
and fibrosis. Significant challenges remain, however, such as the need for non-invasive biomarkers and better models for the disease. At Cambridge Healthtech Institute's Targeting NASH conference, join academic and industry investigators to learn
and discuss with one another drug development progress, challenges and solutions in the arena of treating fatty liver disease.
RECOMMENDED PREMIUM PACKAGE:
Choose 2 Short Courses and 2 Conferences/Training Seminars
September 16 Pre-Conference Short Course: SC1: Immunology Basics: Focusing on Autoimmunity and Cancer
September 17-18 Conference: Targeting NASH
September 18 Dinner Short Course: SC9: Targeted Protein Degradation Using PROTACs, Molecular Glues and More
September 18-19 Conference:
Day 1 | Day 2 | Download Brochure | Speaker Biographies
Monday, September 16
1:00 pm Pre-Conference Short Course Registration
Click here for details on short courses offered.
Tuesday, September 17
7:00 am Registration Open and Morning Coffee
8:00 Organizer's Welcome Remarks
8:05 Chairperson’s Opening Remarks
Claus Kremoser, PhD, CEO, Phenex
8:10 FEATURED PRESENTATION: Thyroid Hormone Receptor Agonists
Rebecca Taub, MD,
CMO & President, R&D, Madrigal Pharmaceuticals
I will present data from clinical studies of resmetirom (MGL-3196). MGL-3196 is an orally administered, small-molecule, liver-directed compound that is currently in Phase III development for NASH. The data show highly significant reduction of liver fat
and biomarkers of inflammation and fibrosis and resolution of NASH on liver biopsy in a 36-week serial liver biopsy study.
8:40 FEATURED PRESENTATION: Parallel Development of Elafibranor and an in vitro Diagnostic (IVD) to Identify Patients for Drug Therapy
Suneil Hosmane, PhD, Executive Vice President, Strategic Development, Genfit
Elafibranor is a first-in-class PPARα/δ agonist which has demonstrated in a Phase 2b study NASH resolution without the worsening of fibrosis while also improving cardio-metabolic risk. Furthermore, NASH resolution correlated with fibrosis
improvement. Elafibranor is safe, tolerable and is now being investigated in Phase III. Additionally, GENFIT is developing a blood-based in vitro diagnostic to identify NASH patients who are at risk of disease progression
and should be considered for therapeutic intervention – a key unmet clinical need.
9:10 Targeting GLP-1 for NASH
Karin Conde-Knape, PhD, Corporate Vice President, Cardiovascular and Liver Disease Research, Novo Nordisk
GLP1 receptor agonists have been successfully positioned for the treatment of diabetes and obesity. It has been documented that weight loss either by dietary or surgical intervention leads to improvement in NASH and fibrosis. Initial clinical data suggests
a beneficial effect of GLP1 receptor agonists in NASH clinical trials. An overview of GLP1 receptor agonism in the treatment of NASH and future directions will be provided.
9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing
10:25 Combinations with ACC Inhibitor for Treating NASH
Archana Vijayakumar, PhD, Research Scientist, Fibrosis, Gilead
Firsocostat (FIR), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCi), improves hepatic steatosis and liver biochemistry in NASH patients, but may increase plasma TGs in patients with pre-existing hypertriglyceridemia. This is likely mediated by
repression of PPARα activity. In diet-induced obese mice, co-administration of fenofibrate, a PPARα agonist, with a liver-targeted FIR analogue ACCi completely normalized elevations in plasma TGs, and improved liver metabolism. The data
suggest that ACCi/fenofibrate combination may improve NASH efficacy more than either monotherapy.
10:55 Combination Therapy for NASH
Marcos Pedrosa, MD, MPH, Global Program Clinical Head, Therapeutic Area Hepatology and Transplantation, Novartis Pharma AG
Several drugs are currently in development for NASH. Beyond monotherapy, there is also an opportunity for combination therapy. Targeting different pathways in this complex disease with many different phenotypes may provide better clinical outcomes. Also increase the possibility for a more personalized treatment, i.e. precision medicine.
11:25 Combining CVC and Tropifexor to Treat NASH
Star Seyedkazemi, PharmD, Associate Vice President, Clinical Development, Liver Therapeutic Area, Allergan
11:55 Accelerating NASH in an Improved Translational Model: MS-NASH Mouse on Western Diet and CCl4
Guodong Zhang, PhD, Director, Cardiovascular and Metabolic Disease, Crown Bioscience
Enhanced models are needed to improve NASH drug development, combining the severe pathology and dysmetabolism seen clinically. Discover the MS-NASH mouse on Western diet, fructose, and CCl4,
a new preclinical NASH model combining both severe fibrosis and dysmetabolism in an accelerated timeframe. Explore model characterization and outcomes following OCA treatment.
12:10 pm Sponsored Presentation (Opportunity Available)
12:25 Session Break
12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:15 Refreshment Break in the Exhibit Hall with Poster Viewing
1:50 Chairperson’s Remarks
Kendra K. Bence, PhD, Senior Director, Metabolism, Internal Medicine Research Unit (IMRU), Pfizer, Inc.
1:55 Are Circulating Fibrosis Biomarkers Useful in NASH Drug Development?
Saurabh Gupta, PhD, Director, Translational Medicine and Early Clinical, Takeda Pharmaceuticals International Co.
Clinical Diagnosis of NASH and evaluation of anti-fibrotic activity in clinical trials heavily relies on the histological readouts based on liver biopsy, a highly invasive, variable and a non-representative technique. We will summarize soluble biomarkers
which have shown most promising results in terms of fibrosis and NASH staging, and measuring the anti-fibrotic activity in clinical trials.
2:25 Federal Landscape for NASH Patients and Products
Barrett Thornhill, JD, Executive Director, NASH Alliance
Washington, DC has become the confluence of products, policy, pricing and access, but NAFLD-NASH is a virtual unknown among federal policymakers. The now-silent public health crisis will grow dramatically in coming years, and the NASH community of clinicians,
innovators and patients is developing the public health infrastructure to better understand NASH implications and support product commercialization. This session will provide an overview of these efforts and explore how federal programs can be a ‘pull
incentive’ that bolsters product development.
2:55 Precision Metabolomics: Understanding the Complexity of NAFLD/NASH
Kari Wong, Senior Study Director, Metabolon, Inc.
Disease drivers including genetics, environmental cues and microbiota drive the development of nonalcoholic-steatohepatitis(NASH). The constellation of factors inciting NASH has spawned a remarkable array of targets. A tool for augmenting the challenges of R&D programs is Metabolon’s Metabolomics platform. By identifying 1000+ metabolites in a single sample across pathways that underly NASH pathogenesis, key insights of target/molecule combinations can be illuminated with this platform. This approach can be applied at any stage of drug development.
3:25 Refreshment Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced
4:05 Drug Development for NASH Cirrhosis
Peter Traber, MD, Partner, Alacrita Consulting; Adjunct Professor of Medicine, University of Pennsylvania School of Medicine
NASH is a chronic, slowly progressive inflammatory and fibrotic disease of the liver which progresses in some individuals to cirrhosis with its attendant complications, including death and liver transplant. In this presentation, the differences in the
pathophysiology and impact on patients between precirrhotic and cirrhotic NASH will be reviewed. Additionally, acceptable and potential regulatory endpoints for clinical trials will be reviewed and put in the context of current ongoing development
programs. The publicly disclosed information on established clinical trial programs in cirrhotic NASH will be reviewed and compared, and thoughts about future clinical development for NASH cirrhosis will be discussed.
4:35 Translational Challenges in NASH
Brad Geddes, PhD, Senior
Director, Innate Immunity Research Unit, GSK
This presentation will focus on recent FDA guidance regarding fibrosis-centric primary endpoints for NASH clinical trials and its impact on preclinical development of potential NASH therapeutics.
5:05 Interactive Breakout Discussion Groups - View All Breakouts
Join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a
Animal Models for NASH
Moderator: Bryan C. Fuchs, PhD, Assistant Professor of Surgery, Harvard Medical School
- Re-evaluating NASH animal models in the context of the new FDA guidelines for NASH cirrhosis
- Which noncirrhotic NASH animal models have the most representative histology?
- Are there NASH cirrhosis animal models that develop complications?
- Which biomarkers will be reflective of improvements in histology or predictive of complications?
Efficacy of MOA in the Treatment of NASH
Moderator: Karin Conde-Knape, PhD, Corporate Vice President, Cardiovascular and Liver Disease Research, Novo Nordisk
- What is the decrease in liver fat telling us?
- What will be the needed efficacy to make a difference to patients?
- Are we any closer to having surrogate markers of efficacy?
Cirrhosis and NASH
Moderator: Peter Traber, MD, Partner, Alacrita Consulting; Adjunct Professor of Medicine, University of Pennsylvania School of Medicine
- Targets in common between chirrhosis and NASH
- Challenges in treating cirrhotic NASH
- Regulatory guidance for cirrhosis NASH trials
6:05 Welcome Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)
7:10 Close of Day
Day 1 | Day 2 | Download Brochure | Speaker Biographies
Wednesday, September 18
7:30 am Registration Open and Morning Coffee
8:00 Chairperson’s Remarks
Weilin Xie, PhD, Senior Principal Scientist, Biotherapeutics, Celgene
8:05 Targeting Integrin αVβ1 for the Treatment of Liver Fibrosis Associated with NASH
PhD, CMO, Pliant Therapeutics
Fibrosis is a common pathway for progression of many debilitating diseases associated with loss of organ function. Integrins play a key role in regulating TGF-β activation and cell-matrix interactions, and thus represent attractive antifibrotic targets.
We evaluated small molecule integrin inhibitors with different selectivity profiles in lung, liver and kidney models of injury and fibrosis, in tissue slices from patients with lung and liver fibrosis, as well as assessed non-invasive
in vivo biomarkers of target engagement.
8:35 Targeting Fructose Metabolism: Update on KHK Inhibitor for NASH
Kendra K. Bence,
PhD, Senior Director, Metabolism, Internal Medicine Research Unit (IMRU), Pfizer, Inc.
Excessive fructose intake leads to increased energy storage in the form of fat as well as accumulation of pro-inflammatory metabolites, both important components in the development of NAFLD and NASH. To understand the specific role of fructose in T2DM
and NAFLD/NASH, we designed and tested a potent, novel, orally-bioavailable inhibitor of ketohexokinase (KHK), the primary enzyme which catalyzes the conversion of fructose to fructose-1-phosphate (F1P) in the first step of fructose metabolism.
View Speaker Interview
9:05 Population-scale Human Genetics and Genomics for NASH Drug Target & Biomarker Discovery
Richard Williams, MBBS, PhD, Global Head, Medicine, WuXi NextCODE
New drug targets & biomarkers are desperately needed for effective NASH therapy, monitoring & prevention.
In our global NASH discovery programs, we are (1) using whole genome sequencing (WGS) to compare thousands of patients with high fibrosis NASH, Low or No fibrosis NASH & NAFL, and population controls, and (2) interrogating hundreds of fresh liver biopsies from NASH & NAFL patients and control individuals with ‘bulk’ multi-omic genomic analysis (WGS, RNA-Seq, DNA methylation), single cell RNA-seq and fully-integrated AI to reveal novel disease biology, drug targets and biomarkers.
9:35 Coffee Break in the Exhibit Hall with Poster Viewing
10:20 Liver X Receptor (LXR) Agonists PX665 for NASH
Claus Kremoser, PhD, CEO, Phenex
The liver X receptor is a nuclear hormone receptor and is therefore similar to other promising NASH targets such as PPARs and FXR. LXRs regulate cholesterol, fatty acid and glucose levels in the cell. We present our results on an LXR inverse agonist,
PX665, which combines antisteatotic, weight lowering, antifibrotic and insulin sensitizing properties in one approach to combat NASH.
10:50 An Antisense DGAT Inhibitor for NASH
Erin Morgan, Executive
Director, Clinical Development, Ionis Pharmaceuticals
DGAT2 catalyzes the terminal step in the synthesis of triacylglycerols from de novo synthesized fatty acids and newly formed diglycerides. In pre-clinical models of NAFLD, we previously reported that specific inhibition of DGAT2 caused a marked improvement
in hepatic steatosis. The talk will discuss results with a Novel antisense inhibitor of diacylglycerol acyltransferase 2 (IONIS-DGAT2RX) administered in NAFLD patients with type 2 diabetes. Results from the international randomized placebo-controlled
Phase 2 trial demonstrated that IONIS DGAT2RX significantly improved hepatic steatosis without causing hypertriglyceridemia or affecting hepatic function in type-2 diabetes mellitus patients with steatosis, supporting further development
of IONIS- DGAT2RX in NASH patients.
11:20 Enjoy Lunch on Your Own
11:20 Conference Registration for Programs 1B-7B
12:20 pm Event Chairperson’s Opening Remarks
An-Dinh Nguyen, Team Lead, Discovery on Target 2019, Cambridge Healthtech Institute
12:30 Plenary Keynote Introduction
Anjan Chakrabarti, Vice President, Discovery Chemistry, Syngene International Ltd
12:40 Base Editing: Chemistry on a Target Nucleotide in the Genome of Living Cells
David R. Liu, PhD, Howard Hughes Medical Institute Investigator, Professor of Chemistry & Chemical Biology, Harvard University
1:20 PROTACs: Past, Present, and Future
Craig M. Crews, PhD, Professor, Chemistry; Pharmacology; Molecular, Cellular & Developmental Biology; Yale University
2:00 Close of Plenary Keynote Program
2:00 Dessert Break in the Exhibit Hall with Poster Viewing
2:45 Close of Targeting NASH Conference
Please click here to continue to the agenda for Targeting Fibrosis
Day 1 | Day 2 | Download Brochure | Speaker Biographies